The Business Research Company’s Cancer Cachexia Global Market Report 2024 – Market Size, Trends, And Market Forecast 2024-2033

LONDON, GREATER LONDON, UK, June 19, 2024 /EINPresswire.com/ -- The global cancer cachexia market is projected to grow from $2.33 billion in 2023 to $2.47 billion in 2024, at a CAGR of 5.9%. This growth can be attributed to factors such as an improved understanding of cancer biology, the prevalence of cancer, an increased aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers. By 2028, the market is expected to reach $3.14 billion, growing at a CAGR of 6.2%, driven by rising awareness about cachexia management, expanding geriatric population, growing adoption of novel therapeutic approaches, rising healthcare expenditure, and favorable government initiatives.

Impact Of Cancer Prevalence On The Cancer Cachexia Market
The increasing prevalence of cancer is expected to propel the growth of the cancer cachexia market going forward. Cancer refers to a condition where abnormal cells proliferate uncontrollably in the body, forming tumors and disrupting normal bodily processes. The cases of cancer are attributed to various factors, including lifestyle changes, environmental factors, an aging population, genetic predisposition, improved diagnostic methods leading to earlier detection, and increased awareness, prompting more people to seek medical attention. Advancements in medical technology and a greater understanding of cancer and its complications are resulting in more frequent diagnoses and reporting of cancer cachexia. Healthcare professionals are improving their ability to identify cachexia symptoms, facilitating earlier interventions and treatment commencement.

Explore comprehensive insights into the global cancer cachexia market with a detailed sample report:
https://www.thebusinessresearchcompany.com/sample_request?id=15527&type=smp

Major Players and Market Trends
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Innovative Treatments In The Cancer Cachexia Market
Major companies operating in the cancer cachexia market are developing innovative medication, such as ghrelin receptor agonists, to address the debilitating symptoms and complications associated with cachexia, aiming to improve patient outcomes and quality of life. A ghrelin receptor refers to a medication that activates the ghrelin receptor in the body, specifically aimed at addressing cancer cachexia.

Segments:
• Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics
• Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions • Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Geographical Insights: North America Leading the Market
North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access the complete report for an in-depth analysis of the global cancer cachexia market:
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Cancer Cachexia Global Market Report 2024 from TBRC covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Cancer Cachexia Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on cancer cachexia market size, cancer cachexia market drivers and trends, cancer cachexia market major players, competitors' revenues, market positioning, and market growth across geographies. The cancer cachexia market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
AI In Cancer Diagnostics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/ai-in-cancer-diagnostics-global-market-report

Appendiceal Cancer Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/appendiceal-cancer-treatment-global-market-report

Anti-Cancer MAbS Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

About The Business Research Company
The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn